Poulabi Banerjee

4.1k citations

48 papers · 1.9k indexed · 1 hit paper · h-index 17

Endocrinology, Diabetes and Metabolism top 2%
- Diabetes, Cardiovascular Risks, and Lipoproteins 6
Cardiology and Cardiovascular Medicine top 2%
- Lipid metabolism and disorders 19
Cancer Research top 5%
- Cancer, Lipids, and Metabolism 17
Surgery top 5%
- Lipoproteins and Cardiovascular Health 28
Ophthalmology top 5%
Economics and Econometrics
- Pharmaceutical Economics and Policy 5
- Health Systems, Economic Evaluations, Quality of Life 4
Genetics
- Genetic Associations and Epidemiology 4
Molecular Biology
- Retinal Development and Disorders 4

Co-authors: Robert Pordy Kuo‐Chen Chan Daniel A. Gipe Daniel Gaudet John J.P. Kastelein Robert S. Rosenson Paolo Rubba Shazia Ali
Cited by: Endocrinology, Diabetes and Metabolism Cardiology and Cardiovascular Medicine Cancer Research
Partner nations: United States Italy France

In The Last Decade

Poulabi Banerjee

48 papers receiving 1.9k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Poulabi Banerjee

Since Specialization

Citations

This map shows the geographic impact of Poulabi Banerjee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Poulabi Banerjee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Poulabi Banerjee more than expected).

Fields of papers citing papers by Poulabi Banerjee

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Poulabi Banerjee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Poulabi Banerjee. The network helps show where Poulabi Banerjee may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Poulabi Banerjee, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Poulabi Banerjee Line = papers co-authored together Poulabi Banerjee links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Treatment With Evinacumab Links a New Pathogenic Variant in the LPL Gene to Persistent Chylomicronemia Miriam Larouche,Poulabi Banerjee,Diane Brisson,Robert Pordy,Daniel Gaudet	2025	2
2	Population Pharmacokinetics and Exposure‐Response Modeling for Evinacumab in Children, Adolescents, and Adults With Homozygous Familial Hypercholesterolemia Sébastien Bihorel,Robert Dingman,Jeanne Mendell,Yuhuan Wang,Poulabi Banerjee,Robert Pordy,John D. Davis,A. Thomas DiCioccio,Lutz Harnisch	2025	2
3	Evinacumab Reduces Triglyceride-Rich Lipoproteins in Patients with Hyperlipidemia: A Post-Hoc Analysis of Three Randomized Clinical Trials Robert S. Rosenson,Daniel J. Rader,Shazia Ali,Poulabi Banerjee,Jennifer McGinniss,Robert Pordy	2024	8
4	Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia Albert Wiegman,Susanne Greber‐Platzer,Shazia Ali,M. Doortje Reijman,Eliot A. Brinton,Min‐Ji Charng,Shubha Srinivasan,Carissa M. Baker‐Smith,Seth J. Baum,Julie A. Brothers,Jacob Hartz,Patrick M. Moriarty,Jeanne Mendell,Sébastien Bihorel,Poulabi Banerjee,Richard T. De George,Boaz Hirshberg,Robert Pordy	2023	41
5	CLINICAL TRIAL WITH THE ANGPTL3 MONOCLONAL ANTIBODY EVINACUMAB IDENTIFIES A NEW RARE CHYLOMICRONEMIA CAUSING VARIANT IN THE LPL GENE M. Larouche,Robert Pordy,Poulabi Banerjee,Daniel Gaudet	2023	1
6	The Long-Term Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia Frederick J. Raal,Robert S. Rosenson,Laurens F. Reeskamp,John J.P. Kastelein,Paolo Rubba,P. Barton Duell,Masahiro Koseki,Erik S.G. Stroes,Shazia Ali,Poulabi Banerjee,Kuo‐Chen Chan,Nagwa Khilla,Jennifer McGinniss,Robert Pordy,Yi Zhang,Daniel Gaudet	2023	15
7	Evinacumab for Homozygous Familial Hypercholesterolemiabreakdown → Frederick J. Raal,Robert S. Rosenson,Laurens F. Reeskamp,G. Kees Hovingh,John J.P. Kastelein,Paolo Rubba,Shazia Ali,Poulabi Banerjee,Kuo‐Chen Chan,Daniel A. Gipe,Nagwa Khilla,Robert Pordy,David M. Weinreich,George D. Yancopoulos,Yi Zhang,Daniel Gaudet	2020	470
8	Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance Rene C. Adam,Ivory J. Mintah,Corey A. Alexa-Braun,Lisa M. Shihanian,Joseph S. Lee,Poulabi Banerjee,Sara Hamon,Hye In Kim,Jonathan C. Cohen,Helen H. Hobbs,Cristopher V. Van Hout,Jesper Gromada,Andrew Murphy,George D. Yancopoulos,Mark W. Sleeman,Viktoria Gusarova	2020	124
9	Functional Analysis of LDLR (Low-Density Lipoprotein Receptor) Variants in Patient Lymphocytes to Assess the Effect of Evinacumab in Homozygous Familial Hypercholesterolemia Patients With a Spectrum of LDLR Activity Poulabi Banerjee,Kuo‐Chen Chan,Michel Tarabocchia,Asier Benito‐Vicente,Ana Catarina Alves,Kepa B. Uribe,Mafalda Bourbon,Paul J. Skiba,Robert Pordy,Daniel A. Gipe,Daniel Gaudet,César Martı́n	2019	64
10	Genetic Polymorphisms Associated with Idiopathic Short Stature and First-Year Response to Growth Hormone Treatment Charmian A. Quigley,Ying Grace Li,Milton R. Brown,Sreekumar Pillai,Poulabi Banerjee,Robin S. Scott,Werner Blum,John S. Parks	2019	1
11	Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES Trial Amy Damask,Philippe Gabríel Steg,Gregory G. Schwartz,Michael Szarek,Emil Hagström,Lina Badimón,M. John Chapman,Cathérine Boileau,Sotirios Tsimikas,Henry N. Ginsberg,Poulabi Banerjee,Garen Manvelian,Robert Pordy,Sibylle Hess,John D. Overton,Luca A. Lotta,George D. Yancopoulos,Gonçalo R. Abecasis,Aris Baras,Charles Paulding	2019	146
12	Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia Joep C. Defesche,Claudia Stefanutti,Gisle Langslet,Paul N. Hopkins,Werner Seiz,Marie T. Baccara‐Dinet,Sara Hamon,Poulabi Banerjee,John J.P. Kastelein	2017	34
13	Abstract 19133: Inhibition of ANGPTL3 by Evinacumab Reduced Triglycerides (TGs) and LDL-C in Subjects Presenting With Modest Elevations in TGs and/or LDL-C, Recapitulating the Hypolipidemic Effects of Loss-of-Function (LoF) Mutations of ANGPTL3 Richard L. Dunbar,Aurelie Bouzelmat,Daniel A. Gipe,Robert Pordy,William J. Sasiela,Scott Mellis,Poulabi Banerjee	2016	2
14	Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method: analysis of 3 randomized trials versus placebo Peter P. Tóth,Sara Hamon,Steven R. Jones,Seth S. Martin,Parag H. Joshi,Krishnaji Kulkarni,Poulabi Banerjee,Corinne Hanotin,Eli M. Roth,James M. McKenney	2016	39
15	EFFICACY OF ALIROCUMAB IN 1,191 PATIENTS WITH A WIDE SPECTRUM OF MUTATIONS IN GENES CAUSATIVE FOR FAMILIAL HYPERCHOLESTEROLEMIA John J.P. Kastelein,Gisle Langslet,Paul N. Hopkins,Joep C. Defesche,Werner Seiz,Marie T. Baccara‐Dinet,Sara Hamon,Poulabi Banerjee,Claudia Stefanutti	2016	1
16	Abstract 15525: Alirocumab, a Fully Human Monoclonal Antibody to Proprotein Convertase Subtilisin/kexin Type 9, and Its Effects on Lipoprotein Subfractions Determined by Ion Mobility Ronald M. Krauss,Poulabi Banerjee,Sara Hamon,Corinne Hanotin,William J. Sasiela,Michael J. Koren,James M. McKenney	2014	1
17	EFFECTS OF ALIROCUMAB, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9, ON LIPOPROTEIN PARTICLE CONCENTRATIONS DETERMINED BY NUCLEAR MAGNETIC RESONANCE: SUBSTUDY OF A RANDOMIZED DOUBLE-BLIND PHASE II CLINICAL TRIAL Michael J. Koren,Dean J. Kereiakes,Ray Pourfarzib,Deborah A. Winegar,Poulabi Banerjee,Sara Hamon,Corinne Hanotin,James M. McKenney	2014	2
18	An association study of 43 SNPs in 16 candidate genes with atorvastatin response John F. Thompson,M. Man,Keith Johnson,Linda S. Wood,Maruja E. Lira,David B. Lloyd,Poulabi Banerjee,Patrice M. Milos,S P Myrand,J Paulauskis,Mark A. Milad,William J. Sasiela	2005	165
19	Application of pooled genotyping to scan candidate regions for association with HDL cholesterol levels David A. Hinds,Albert Seymour,L. Kathryn Durham,Poulabi Banerjee,Dennis G. Ballinger,Patrice M. Milos,David R. Cox,John F. Thompson,Kelly A. Frazer	2004	53
20	TULP1 mutation in two extended Dominican kindreds with autosomal recessive Retinitis pigmentosa Poulabi Banerjee,Patrick W. Kleyn,James A. Knowles,Charles A. Lewis,Barbara M. Ross,Enrico Parano,Steve G. Kovats,John J. Lee,Graciela K. Penchaszadeh,Jürg Ott,Samuel G. Jacobson,T. Conrad Gilliam	1998	122

About Poulabi Banerjee

Poulabi Banerjee is a scholar working on Cancer Research, Cardiology and Cardiovascular Medicine and Surgery, having authored 48 papers that have together received 1.9k indexed citations. Recurring topics across this work include Lipoproteins and Cardiovascular Health (28 papers), Lipid metabolism and disorders (19 papers), Cancer, Lipids, and Metabolism (17 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (6 papers), Pharmaceutical Economics and Policy (5 papers), Genetic Associations and Epidemiology (4 papers), Retinal Development and Disorders (4 papers) and Health Systems, Economic Evaluations, Quality of Life (4 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (588 citations), Cardiology and Cardiovascular Medicine (799 citations) and Cancer Research (416 citations). Poulabi Banerjee has collaborated with scholars based in United States, Italy and France. Frequent co-authors include Robert Pordy, Kuo‐Chen Chan, Daniel A. Gipe, Daniel Gaudet, John J.P. Kastelein, Robert S. Rosenson, Paolo Rubba, Shazia Ali, George D. Yancopoulos and Sara Hamon.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact